CORDIS
EU research results

CORDIS

English EN
Novel anticancer therapeutics based on modulation of apoptosis through dependence receptors

Novel anticancer therapeutics based on modulation of apoptosis through dependence receptors

Objective

Since 1998, a new concept has emerged, based on the notion that a receptor unoccupied by its ligand is not necessarily inactive. Rather, such a receptor can mediate two different signalling pathways, depending on whether or not it is bound by its ligand. In the absence of ligand, signalling leads to an active process that results in cell death through apoptosis. The survival of a cell expressing such a receptor can therefore be seen as dependent on the presence of the ligand, hence the concept of 'dependence receptors' (DR).
The fact that the different DRs trigger apoptosis in the absence of ligand suggests that they may all act as regulators of tumorigenesis. In addition, expression of DRs is lost or decreased in many tumours, suggesting that they act as tumour suppressors and that their loss represents a selective advantage for tumoral cells. HERMIONE proposes that unravelling the link between different DRs (DCC, UNC5H, KAI1 and RET), downstream molecules and apoptosis will lead to the identification of new potential targets for anti-cancer drugs. HERMIONE will provide a better understanding of the signalling pathways acting downstream of DRs, observe the association of mutations with the onset and progression of tumours (grade, prognosis) and generate murine models in which the apoptotic signalling of the DR is turned off to study the implication of DRs in tumorigenesis in vivo. Through this, HERMIONE will generate knowledge on DR signalling pathways involved in the apoptosis of tumoral cells (colorectal, breast, thyroid and prostate cancers) and use the general concept of DRs to select and perform pre-clinical testing of novel anti-cancer drugs. The HERMIONE consortium gathers leading academics in the fields of DR, death signalling and cancer genetics, a biotechnology SME specialised in the production of reagents, a major pharmaceutical company and a consulting firm specialised in communication and dissemination activities/ project management.'

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CENTRE LÉON BÉRARD

Address

28, Rue Laennec
Lyon

France

Administrative Contact

Patrick MEHLEN (Dr)

Participants (7)

Sort alphabetically

Expand all

ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA

Italy

APOTECH CORPORATION

Switzerland

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

United Kingdom

INSTITUT DE RECHERCHE SERVIER

France

COMMISSARIAT A L'ENERGIE ATOMIQUE

France

ALMA CONSULTING GROUP SAS

France

UNIVERSITÉ DE LAUSANNE

Switzerland

Project information

Grant agreement ID: 37530

  • Start date

    1 November 2006

  • End date

    31 October 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 3 334 736

  • EU contribution

    € 2 364 909

Coordinated by:

CENTRE LÉON BÉRARD

France